Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

Tatsui Otsuka, Takashi Togo, Naoya Sugiyama, Kumi Uehara, Asuka Yoshimi, Aya Karashima, Hiromi Shioya, Yoshio Hirayasu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Obsessive-compulsive disorder (OCD) is often complicated by depression. We report on a patient with treatment-refractory OCD and treatment-refractory major depression who demonstrated a robust response to augmentation of paroxetine with perospirone. Perospirone is a second-generation antipsychotic agent with antagonist effects on both serotonin 5-HT2A and dopamine D2 receptors, as well as a unique agonist effects on serotonin 5-HT1A receptors. Future studies would be valuable to elucidate the utility of augmentation therapy of selective serotonin reuptake inhibitors with perospirone in the treatment of refractory OCD with depression.

Original languageEnglish
Pages (from-to)564-566
Number of pages3
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume31
Issue number2
DOIs
Publication statusPublished - 2007 Mar 30
Externally publishedYes

Keywords

  • Augmentation therapy
  • Depression
  • Obsessive-compulsive disorder
  • Perospirone

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression'. Together they form a unique fingerprint.

  • Cite this